Cuba has unveiled its first manufactured nanopharmaceutical drug—a tweaked variety of cyclosporine, used to help prevent transplant rejection—official media reported Saturday.
Sep 23, 2012
not rated yet
1
A new system for delivering a drug to organ transplant patients, which could avoid the risk of harmful side effects, is being developed by scientists at the University of Strathclyde in Glasgow.
Jan 26, 2012
5 / 5 (1)
1
Researchers at Erasmus MC University Medical Centre in The Netherlands found that cyclosporine treatment is a significant risk factor for the development of de novo cancer in liver transplant patients. Full details appear ...
Jun 24, 2010
not rated yet
0
Two-year results from phase III clinical trials show the experimental immunosuppressive drug belatacept can better preserve kidney function in kidney transplant recipients while preventing graft rejection when compared with ...
May 03, 2010
not rated yet
0
Drugs taken by kidney transplant recipients to prevent organ rejection carry similar risks of cancer, according to a study appearing in an upcoming issue of the Journal of the American Society Nephrology (JASN). The result ...
Apr 29, 2010
not rated yet
1
Initial results of a study conducted at 100 centers worldwide indicate that belatacept, a first-in-class costimulation blocker can prevent the immune system rejecting new organs. The results also suggest that it may provide ...
Feb 17, 2010
not rated yet
0
The U.S. Patent and Trademark Office is reviewing a University of Rhode Island pharmacy professor's proposal to use saliva as a non-invasive way to monitor concentrations of anti-rejection drugs in patients that undergo transplants.
Apr 03, 2009
not rated yet
0
A topical eye emulsion consisting of cyclosporine (a medication used to reduce transplant rejections or to treat arthritis and psoriasis) may be a cost-effective treatment for dry eye syndrome that does not respond to other ...
Feb 09, 2009
5 / 5 (1)
0
